Navigation Links
Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/29/2008

PT. RICHMOND, Calif., Jan. 29 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President & Chief Executive Officer, will present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference at the Grand Hyatt Hotel in New York City on Tuesday, February 5, 2008 at 8:40 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to file an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 has completed a successful dose ranging trial for the treatment of alcohol use disorder and a full clinical development program has begun. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com


SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
2. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
5. Amylin Pharmaceuticals Reports 2007 Financial Results
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...LE, PA The American Nurses Credentialing Center (...) as a Magnet hospital. The news came via a confer...taff who broke out with cheers and applause., GMC...itals and only 294 hospitals in the United States... hospitals are eligible for this recognition., "A...
(Date:10/10/2008)...ggests poor self-care partly to blame , ,...f Medicare beneficiaries who have diabetes, being ... according to a new study. , Publishing in th...l Medicine , researchers from the University of Wa...erage age of 75.6 years) who had diabetes and were...
(Date:10/10/2008)... Honoring excellence in the imple... Healthcare Information and Management Systems Soc...Davies Awards in the Organizational, Ambulatory an... Chicago, IL (PRWEB) October 1...on of electronic health records (EHRs), the Healt...
(Date:10/10/2008)...YORK, Oct. 10 /PRNewswire/ -- The Johns Hopkins Un...ultimedia educational program,"Optimizing Adjuvan...atment,Selection," to present recent key research ...ment., In recent years, advancements in the treat... and biologic treatment combinations that are,incr...
Breaking Medicine News(10 mins):Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2
...People with HIV/AIDS in the Northeast say that the...ial stigma is being attached to them// . "I have...sat a few meters away from me, and didn't even loo.... I always thought journalists would help in break...
...Modern three-dimensional radiation therapy has bee...er than older two-dimensional radiation therapy fo...ccording to a new study in the September 1, 2006 e...Oncology * Biology * Physics, the official journal...
...The Delhi government has cleared five healthcare a...i Planning and Finance Minister A.K. Walia said th... and one pertaining to environment - have been giv...ce committee (EFC). The government has sanctioned...
...Amanda Bryson of Inverness has criticized Advanced...apy for her multiple sclerosis. She says that the ...nts and her illness has not improved. Speaking to...ryson said, "I'm back to where I was before the tr...
Other Medicine News:Health News:Modern Radiation Therapy ups Lung Cancer Survival 2
(Date:10/7/2008)...ANSE taken once-daily significantly,improved the s...t. 7 /- Shire plc (LSE: SHP...utical company, today,announced that a study publi...ical Psychiatry found once-daily VYVANSE significa...rder (ADHD) symptoms in adults within,the first we...
(Date:10/7/2008)... Annual Scientific Meeting -, ORLANDO, Fla., Oct....als, Inc. (formerly Microbia, Inc.) and Forest Lab...presentation of results from a Phase,2b study asse...ients with,irritable bowel syndrome with constipat...nce- daily oral dosing of linaclotide, across a ra...
(Date:10/7/2008)...re/ -- Aerovance Inc. today reported,pharmacokinet...s Aerovant,inhalation powder that demonstrate good...following asthma patients, inhalation of a single ...of three doses investigated in,Aerovance,s Phase I... early,next year. Evidence gathered from nonclinic...
(Date:10/7/2008)...acebo-Controlled Phase II Study Shows Sta... MOUNTAIN VIEW, California, October 7 /PRNewswire...ature Phase II data from the,therapeutic prostate ...n,obtained as part of the recently entered partner...he US., The results from the Phase II prospective...
Breaking Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting 2238 1Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting 2238 2AARP and AMA to President Bush Dont Veto Kids Health 2235 1AARP and AMA to President Bush Dont Veto Kids Health 2235 2AARP and AMA to President Bush Dont Veto Kids Health 2235 3Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 2232 1Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 2232 2Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 2232 3Kaiser Permanente Study Shows One in Seven Women are Depressed Before During or After Pregnancy 2229 1Kaiser Permanente Study Shows One in Seven Women are Depressed Before During or After Pregnancy 2229 2Kaiser Permanente Study Shows One in Seven Women are Depressed Before During or After Pregnancy 2229 3
...0,2007-The U.S. Food and Drug,Administration (FDA)...rs to the availability of audio broadcasts that pr...asts, commonly known as,podcasts, can be transmitt...s. , The service is part of the agency,s ongoing e...cerning the safety of,marketed medications when un...
...60th Annual Meeting of the American,Psychiatric As...irstCall/ -- In adults with,major depressive disor... (ADT) resulted in significant improvement in the ...n Rating Scale (MADRS),Total Score. In this six-we... here at the 160th Annual Meeting of the American,...
Other Medicine Technology:FDA Announces Audio Broadcasts on Emerging Drug Safety Information 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8
Laser hair removal for all skin types, including tanned skin. Used for leg and facial veins, non-invasive skin treatment. Offers a large spot sizes with high repetition rates for fast treatment. A
The Soft THORACOPORT™ has a cannula that is less rigid from a side to side perspective than the standard THORACOPORT™ , ,THORACOPORT™ devices are trocars used to gain access to th
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System.
VersaStep™ Reposable Sterilization Trays.
Medicine Products: